vs
Side-by-side financial comparison of Hologic (HOLX) and Roper Technologies (ROP). Click either name above to swap in a different company.
Roper Technologies is the larger business by last-quarter revenue ($2.1B vs $1.0B, roughly 2.0× Hologic). Hologic runs the higher net margin — 17.1% vs 15.8%, a 1.3% gap on every dollar of revenue. On growth, Roper Technologies posted the faster year-over-year revenue change (11.3% vs 2.5%). Roper Technologies produced more free cash flow last quarter ($507.0M vs $215.2M). Over the past eight quarters, Roper Technologies's revenue compounded faster (10.5% CAGR vs 1.5%).
Hologic, Inc. is an American medical technology company primarily focused on women's health; it sells medical devices for diagnostics, surgery, and medical imaging.
Roper Technologies, Inc. is a holding company that owns companies in the technology sector.
HOLX vs ROP — Head-to-Head
Income Statement — Q1 FY2026 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $1.0B | $2.1B |
| Net Profit | $179.1M | $331.0M |
| Gross Margin | 56.0% | 69.4% |
| Operating Margin | 22.6% | 27.2% |
| Net Margin | 17.1% | 15.8% |
| Revenue YoY | 2.5% | 11.3% |
| Net Profit YoY | -10.9% | 53.7% |
| EPS (diluted) | $0.79 | $4.87 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $2.1B | ||
| Q4 25 | $1.0B | $2.1B | ||
| Q3 25 | $1.0B | $2.0B | ||
| Q2 25 | $1.0B | $1.9B | ||
| Q1 25 | $1.0B | $1.9B | ||
| Q4 24 | $1.0B | $1.9B | ||
| Q3 24 | $988.0M | $1.8B | ||
| Q2 24 | $1.0B | $1.7B |
| Q1 26 | — | $331.0M | ||
| Q4 25 | $179.1M | $428.4M | ||
| Q3 25 | $187.2M | $398.5M | ||
| Q2 25 | $194.9M | $378.3M | ||
| Q1 25 | $-17.4M | $331.1M | ||
| Q4 24 | $201.0M | $462.3M | ||
| Q3 24 | $178.6M | $367.9M | ||
| Q2 24 | $194.5M | $337.1M |
| Q1 26 | — | 69.4% | ||
| Q4 25 | 56.0% | 69.5% | ||
| Q3 25 | 55.6% | 69.5% | ||
| Q2 25 | 56.3% | 69.2% | ||
| Q1 25 | 37.5% | 68.7% | ||
| Q4 24 | 56.8% | 68.3% | ||
| Q3 24 | 56.4% | 69.2% | ||
| Q2 24 | 55.4% | 69.5% |
| Q1 26 | — | 27.2% | ||
| Q4 25 | 22.6% | 28.6% | ||
| Q3 25 | 22.6% | 28.4% | ||
| Q2 25 | 24.9% | 28.2% | ||
| Q1 25 | -0.7% | 27.9% | ||
| Q4 24 | 22.5% | 28.0% | ||
| Q3 24 | 23.3% | 28.1% | ||
| Q2 24 | 24.1% | 28.8% |
| Q1 26 | — | 15.8% | ||
| Q4 25 | 17.1% | 20.8% | ||
| Q3 25 | 17.8% | 19.8% | ||
| Q2 25 | 19.0% | 19.5% | ||
| Q1 25 | -1.7% | 17.6% | ||
| Q4 24 | 19.7% | 24.6% | ||
| Q3 24 | 18.1% | 20.8% | ||
| Q2 24 | 19.2% | 19.6% |
| Q1 26 | — | $4.87 | ||
| Q4 25 | $0.79 | $3.97 | ||
| Q3 25 | $0.84 | $3.68 | ||
| Q2 25 | $0.86 | $3.49 | ||
| Q1 25 | $-0.08 | $3.06 | ||
| Q4 24 | $0.87 | $4.29 | ||
| Q3 24 | $0.75 | $3.40 | ||
| Q2 24 | $0.82 | $3.12 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $2.4B | $382.9M |
| Total DebtLower is stronger | $2.5B | $9.7B |
| Stockholders' EquityBook value | $5.2B | $18.8B |
| Total Assets | $9.2B | $34.6B |
| Debt / EquityLower = less leverage | 0.48× | 0.52× |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $382.9M | ||
| Q4 25 | $2.4B | $297.4M | ||
| Q3 25 | $2.2B | $320.0M | ||
| Q2 25 | $1.9B | $242.4M | ||
| Q1 25 | $1.6B | $372.8M | ||
| Q4 24 | $2.0B | $188.2M | ||
| Q3 24 | $2.3B | $269.6M | ||
| Q2 24 | $2.4B | $251.5M |
| Q1 26 | — | $9.7B | ||
| Q4 25 | $2.5B | $9.3B | ||
| Q3 25 | $2.5B | — | ||
| Q2 25 | $2.5B | — | ||
| Q1 25 | $2.5B | — | ||
| Q4 24 | $2.5B | $7.6B | ||
| Q3 24 | $2.5B | — | ||
| Q2 24 | $2.5B | — |
| Q1 26 | — | $18.8B | ||
| Q4 25 | $5.2B | $19.9B | ||
| Q3 25 | $5.0B | $20.0B | ||
| Q2 25 | $4.8B | $19.6B | ||
| Q1 25 | $4.6B | $19.2B | ||
| Q4 24 | $4.8B | $18.9B | ||
| Q3 24 | $5.1B | $18.5B | ||
| Q2 24 | $5.0B | $18.1B |
| Q1 26 | — | $34.6B | ||
| Q4 25 | $9.2B | $34.6B | ||
| Q3 25 | $9.0B | $34.6B | ||
| Q2 25 | $8.8B | $33.2B | ||
| Q1 25 | $8.5B | $31.4B | ||
| Q4 24 | $8.7B | $31.3B | ||
| Q3 24 | $9.2B | $31.6B | ||
| Q2 24 | $8.9B | $29.8B |
| Q1 26 | — | 0.52× | ||
| Q4 25 | 0.48× | 0.47× | ||
| Q3 25 | 0.50× | — | ||
| Q2 25 | 0.52× | — | ||
| Q1 25 | 0.55× | — | ||
| Q4 24 | 0.53× | 0.40× | ||
| Q3 24 | 0.49× | — | ||
| Q2 24 | 0.51× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $229.9M | — |
| Free Cash FlowOCF − Capex | $215.2M | $507.0M |
| FCF MarginFCF / Revenue | 20.5% | 24.2% |
| Capex IntensityCapex / Revenue | 1.4% | 0.5% |
| Cash ConversionOCF / Net Profit | 1.28× | — |
| TTM Free Cash FlowTrailing 4 quarters | $1.0B | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $229.9M | $738.0M | ||
| Q3 25 | $355.1M | $869.5M | ||
| Q2 25 | $343.3M | $404.1M | ||
| Q1 25 | $169.4M | $528.7M | ||
| Q4 24 | $189.3M | $722.2M | ||
| Q3 24 | $367.0M | $755.4M | ||
| Q2 24 | $405.8M | $384.1M |
| Q1 26 | — | $507.0M | ||
| Q4 25 | $215.2M | — | ||
| Q3 25 | $341.4M | — | ||
| Q2 25 | $330.5M | — | ||
| Q1 25 | $153.9M | — | ||
| Q4 24 | $172.5M | — | ||
| Q3 24 | $350.6M | — | ||
| Q2 24 | $385.3M | — |
| Q1 26 | — | 24.2% | ||
| Q4 25 | 20.5% | — | ||
| Q3 25 | 32.5% | — | ||
| Q2 25 | 32.3% | — | ||
| Q1 25 | 15.3% | — | ||
| Q4 24 | 16.9% | — | ||
| Q3 24 | 35.5% | — | ||
| Q2 24 | 38.1% | — |
| Q1 26 | — | 0.5% | ||
| Q4 25 | 1.4% | — | ||
| Q3 25 | 1.3% | — | ||
| Q2 25 | 1.3% | — | ||
| Q1 25 | 1.5% | — | ||
| Q4 24 | 1.6% | — | ||
| Q3 24 | 1.7% | — | ||
| Q2 24 | 2.0% | — |
| Q1 26 | — | — | ||
| Q4 25 | 1.28× | 1.72× | ||
| Q3 25 | 1.90× | 2.18× | ||
| Q2 25 | 1.76× | 1.07× | ||
| Q1 25 | — | 1.60× | ||
| Q4 24 | 0.94× | 1.56× | ||
| Q3 24 | 2.05× | 2.05× | ||
| Q2 24 | 2.09× | 1.14× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
HOLX
| Molecular Diagnostics | $255.3M | 24% |
| Breast Imaging | $219.9M | 21% |
| Services | $216.4M | 21% |
| Capital Equipment Componentsand Software | $187.2M | 18% |
| Cytology Perinatal | $76.0M | 7% |
| Interventional Breast Solutions | $71.2M | 7% |
| Blood Screening | $8.4M | 1% |
| Other Typeof Revenue | $5.4M | 1% |
ROP
Segment breakdown not available.
